LEADER 00921nam2-22003251i-450- 001 990000868350403321 005 20001010 035 $a000086835 035 $aFED01000086835 035 $a(Aleph)000086835FED01 035 $a000086835 100 $a20001010d--------km-y0itay50------ba 101 0 $aita 105 $ay-------001yy 200 1 $a1 : parte prima II, 544 p.parte seconda 441 p. 205 $a2.ed.amp. 210 $aTorino$cTirrenia$d1970 215 $av. (p. 981 compless.) 24 cm 300 $aIl volume I è diviso in due parti 461 0$1001000083473$12001$aTopologia Generale 676 $a514.322 700 1$aDemaria,$bCarlo Davide$0344346 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000868350403321 952 $a000086835000001$fFINBN 959 $aFINBN 996 $a1 : parte prima II, 544 p.parte seconda 441 p$9349326 997 $aUNINA DB $aING01 LEADER 01621nam 2200421 a 450 001 9910695777503321 005 20070322102646.0 035 $a(CKB)5470000002372003 035 $a(OCoLC)86106712 035 $a(EXLCZ)995470000002372003 100 $a20070322d2007 ua 0 101 0 $aeng 135 $aurmn|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPrescription drugs$b[electronic resource] $eoversight of drug pricing in federal programs : testimony before the Committee on Oversight and Government Reform, House of Representatives /$fstatement of John E. Dicken 210 1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2007] 215 $a13 pages $cdigital, PDF file 225 1 $aTestimony ;$vGAO-07-481 T 300 $aTitle from title screen (viewed on Mar. 8, 2006). 300 $a"For release ... February 9, 2007." 300 $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548. 320 $aIncludes bibliographical references. 517 $aPrescription drugs 606 $aDrugs$xPrices$zUnited States 606 $aMedicare 615 0$aDrugs$xPrices 615 0$aMedicare. 700 $aDicken$b John E$01382684 712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Government Reform and Oversight. 712 02$aUnited States.$bGovernment Accountability Office. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910695777503321 996 $aPrescription drugs$93435639 997 $aUNINA